Tony Mok - Concepedia

Author

Tony Mok

Also Known As

Macy Tong, Martin Edelman, Martin Reck, Mok, Mok T S K, Mok, Tony S. K., Patrick M. Forde, R G Martins, S. Mok, S.-T. Mok

1.1K

Publications

105.4K

Citations

130

H-Index

176

Concepts

All Affiliations

Chinese University of Hong Kong Prince of Wales Hospital Guangdong Academy of Medical Sciences Guangdong General Hospital National Taiwan University Hospital

About

Tony Mok is an author at Chinese University of Hong Kong specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	67	219	25.4K
2	Health Sciences	29	54	5K
3	Engineering	4	4	477
4	Natural Sciences	3	3	365
5	Nursing	1	1	79

Tony Mok

402

Publications

87.1K

Citations

113

H-Index

Page 1

	Year	Citations
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma Tony Mok, Yi‐Long Wu, Sumitra Thongprasert, New England Journal of Medicine	2009	8.2K
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling Jeffrey A. Engelman, Kreshnik Zejnullahu, Tetsuya Mitsudomi, Science	2007	4.4K
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer Alice T. Shaw, Dong‐Wan Kim, Kazuhiko Nakagawa, New England Journal of Medicine	2013	3.4K
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer Leora Horn, Aaron S. Mansfield, Aleksandra Szczęsna, New England Journal of Medicine	2018	3.3K
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial Tony Mok, Yi‐Long Wu, Iveta Kudaba, The Lancet	2019	3.2K
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer Tony Mok, Yi‐Long Wu, Myung‐Ju Ahn, New England Journal of Medicine	2016	3.2K
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer Benjamin Solomon, Tony Mok, Dong‐Wan Kim, New England Journal of Medicine	2014	3.2K
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations Lecia V. Sequist, James Chih‐Hsin Yang, Nobuyuki Yamamoto, Journal of Clinical Oncology	2013	3.2K
Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer Solange Peters, D. Ross Camidge, Alice T. Shaw, New England Journal of Medicine	2017	2.4K
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up David Planchard, Sanjay Popat, Keith M. Kerr, Annals of Oncology	2018	2.2K

Page 1